Seres Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Great. Good afternoon, everybody. Thank you for joining us. I'm Terence Flynn, the biopharma analyst at Goldman Sachs, and we're very pleased to have Seres Therapeutics with us. Today from the company we have Eric Shaff, President and CEO; Matt Henn, Chief Scientific Officer; and Lisa von Moltke, who's Chief Medical Officer. Thank you all for joining us. Really appreciate your time today.
Maybe just to get started, was wondering if you could just give a brief overview of the company and the current development programs for those of us that aren't as familiar with the company.
Sure, Terence, and thank you, again, for having us here today. Thanks to Goldman for having us here to talk about Seres and what we think is going to be an incredibly important year for the company and for the microbiome space.
Before I start, I'll just note, we will be making forward-looking statements. So as usual, please refer to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |